image credit: Pixabay

Why Cell and Gene Therapies Need a Paradigm Shift to Enable Commercial Scale-up

June 1, 2020

Via: BioSpace

Cell and gene therapies must scale up on an industrial level if they are to deliver their full potential to patients worldwide, according to speakers at the International Society of Cell Therapy meeting, ISCT Paris 2020 Virtual, May 29.

“As the industry moves from clinical to commercial, we are reaching an inflection point and face key challenges,” Alberto Santagastino, VP, head of the cell and gene technologies business unit at Lonza, said. Chief among them are improving process development and addressing the manufacturing pressures of technology, timeline, and costs. “We need to look at the practicalities of how to make therapies available.”

Read More on BioSpace